Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging
Reference8 articles.
1. Ryoo HG, Suh M, Paeng JC, Chung J-K. Short essay on 60 years’ challenges and achievements of KSNM. Nucl Med Mol Imag. 2021;55:2–6.
2. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.
3. FDA approves first PSMA-targeted PET imaging drug for men with prostate cancer. https://www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer. Accessed 4 Apr 2021.
4. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. 177Lu-PSMA-617 versus cabazitaxel in metastatic castration resistant prostate cancer. Lancet. 2021;397:797–804. https://doi.org/10.1016/S0140-6736(21)00237-3.
5. Phase 3 trial of 177Lu-PSMA-617 meets survival end points. https://www.cancernetwork.com/view/phase-3-trial-of-177lu-psma-617-meets-survival-end-points. Accessed 4 Apr 2021.